DeepMed Research

Haemagglutinin-strain A(H1N1)

Generic Name: Haemagglutinin-strain A(H1N1)

Brand Names: Afluria Tetra, Agriflu, FluLaval Tetra, Fluad, Fluad Pediatric, Fluviral, Fluzone High-Dose Quadrivalent, Fluzone Quadrivalent, Influvac Tetra

Drug Type: Biotech

Clinical Trials

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Completed

Conditions: Influenza Immunization (Healthy Volunteers)

Interventions: Biological: Quadrivalent Influenza Vaccine
Biological: High-Dose Quadrivalent Influenza Vaccine

First Posted Date: 2023-09-28

Last Posted Date: 2025-03-24

Lead Sponsor: Sanofi

Target Recruit Count: 2078

Registration Number: NCT06059456

Locations: 🇫🇮
Investigational Site Number : 2460001, Helsinki, Finland
🇩🇪
Investigational Site Number : 2760010, Martinsried, Germany
🇩🇪
Investigational Site Number : 2760003, Martinsried, Germany

and more 8 locations

Cost-effectiveness of the Influenza Vaccination

Phase 4

Recruiting

Conditions: Influenza Vaccine
Vaccination
Cost-Effectiveness

Interventions: Drug: Quadrivalent Influenza Vaccine

First Posted Date: 2023-08-18

Last Posted Date: 2023-08-18

Lead Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh

Target Recruit Count: 2567

Registration Number: NCT05996549

Locations: 🇧🇩
Rajshahi Medical College Hospital, Rajshahi, Bangladesh

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

Completed

Conditions: Influenza, Human
COVID-19

Interventions: Biological: Comirnaty
Biological: Quadrivalent Influenza Vaccine

First Posted Date: 2023-05-15

Last Posted Date: 2023-06-01

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05858450

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Phase 3

Completed

Conditions: Influenza, Human

Interventions: Biological: Quadrivalent influenza vaccine
Biological: Quadrivalent influenza modRNA vaccine

First Posted Date: 2022-09-14

Last Posted Date: 2025-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 45789

Registration Number: NCT05540522

Locations: 🇳🇿
P3 Research - Wellington, Wellington, New Zealand
🇵🇭
De La Salle Health Sciences Institute, Dasmarinas City, Philippines
🇵🇭
De La Salle Medical and Health Sciences Institute, Dasmarinas, Philippines

and more 296 locations

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Phase 4

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Biological: Quadrivalent influenza vaccine
Drug: iDMT
Drug: Ofatumumab

First Posted Date: 2020-12-14

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 63

Registration Number: NCT04667117

Locations: 🇺🇸
The MS Center for Innovation in Care, Saint Louis, Missouri, United States
🇺🇸
Hope Research Institute Center Neurology and Spine, Phoenix, Arizona, United States
🇺🇸
Infinity Clinical Research LLC, Hollywood, Florida, United States

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Phase 4

Recruiting

Conditions: Influenza

Interventions: Drug: Fluzone
Drug: Flucelvax
Drug: Fluzone High-Dose
Drug: Fluad

First Posted Date: 2019-09-24

Last Posted Date: 2024-07-11

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 50

Registration Number: NCT04101838

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care

Phase 4

Completed

Conditions: Flu

Interventions: Drug: Fluzone HD Vaccine
Drug: Fluad Vaccine

First Posted Date: 2018-10-03

Last Posted Date: 2024-04-30

Lead Sponsor: David H. Canaday

Target Recruit Count: 478

Registration Number: NCT03694808

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States

Gene Signatures of Influenza Vaccine Responses in Older Adults

Phase 4

Completed

Conditions: Influenza

Interventions: Drug: Fluad Vaccine
Drug: Fluzone High-Dose

First Posted Date: 2018-07-27

Last Posted Date: 2023-05-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 241

Registration Number: NCT03603509

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Effects of Aging on Primary and Secondary Vaccine Responses

Phase 1

Completed

Conditions: Typhoid
Healthy Adults
Influenza
Hepatitis A

Interventions: Biological: Typhim Vi
Biological: Vaqta
Biological: Fluzone® quadrivalent
Biological: Fluad
Biological: Fluzone High Dose
Biological: Vivotif

First Posted Date: 2017-10-18

Last Posted Date: 2024-12-16

Lead Sponsor: Stanford University

Target Recruit Count: 54

Registration Number: NCT03312699

Locations: 🇺🇸
Stanford LPCH Vaccine Program, Stanford, California, United States

Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Fluad
Biological: Fluzone

First Posted Date: 2016-08-18

Last Posted Date: 2024-11-21

Lead Sponsor: McMaster University

Target Recruit Count: 3425

Registration Number: NCT02871206

Locations: 🇨🇦
McMaster University, Hamilton, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy